Stifel Downgrades Neumora Therapeutics (NMRA) to Hold
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Guggenheim Downgrades Neumora Therapeutics (NMRA) to Neutral
March 7, 2025 7:52 AM ESTGuggenheim analyst Yatin Suneja downgraded Neumora Therapeutics (NASDAQ: NMRA) from Buy to Neutral.
The analyst comments "Key Message: Following yesterday's announcement by JNJ that the company is discontinuing its Phase 3 VENTURA program testing aticaprant (KORA) as an adjunctive treatment for major depressive... More
